HIV Associated Lipodystrophy Syndrome Treatment Market, Global Outlook and Forecast 2022-2028

March 2022 | 67 pages | ID: H87A954AD433EN
Market Monitor Global

Abstracts

Lipodystrophy syndrome groups together three clinical conditions characterized by abnormal body fat distribution: lipoatrophy, lipoaccumulation and a mixed syndrome.

This report contains market size and forecasts of HIV Associated Lipodystrophy Syndrome Treatment in Global, including the following market information:

Global HIV Associated Lipodystrophy Syndrome Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global HIV Associated Lipodystrophy Syndrome Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Specific Drug Treatment Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of HIV Associated Lipodystrophy Syndrome Treatment include Gilead Sciences, Amgen, Abbott, AstraZeneca, AbbVie, GlaxoSmithKline, Alfa Wassermann SPA, Theratechnologies and Bristol-Myers Squibb. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the HIV Associated Lipodystrophy Syndrome Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global HIV Associated Lipodystrophy Syndrome Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global HIV Associated Lipodystrophy Syndrome Treatment Market Segment Percentages, by Type, 2021 (%)

• Specific Drug Treatment
• Cosmetic Corrective Treatment

Global HIV Associated Lipodystrophy Syndrome Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global HIV Associated Lipodystrophy Syndrome Treatment Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Specialist Clinic
• Others

Global HIV Associated Lipodystrophy Syndrome Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global HIV Associated Lipodystrophy Syndrome Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies HIV Associated Lipodystrophy Syndrome Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies HIV Associated Lipodystrophy Syndrome Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Gilead Sciences
• Amgen
• Abbott
• AstraZeneca
• AbbVie
• GlaxoSmithKline
• Alfa Wassermann SPA
• Theratechnologies
• Bristol-Myers Squibb

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 HIV Associated Lipodystrophy Syndrome Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global HIV Associated Lipodystrophy Syndrome Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL HIV ASSOCIATED LIPODYSTROPHY SYNDROME TREATMENT OVERALL MARKET SIZE

2.1 Global HIV Associated Lipodystrophy Syndrome Treatment Market Size: 2021 VS 2028
2.2 Global HIV Associated Lipodystrophy Syndrome Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top HIV Associated Lipodystrophy Syndrome Treatment Players in Global Market
3.2 Top Global HIV Associated Lipodystrophy Syndrome Treatment Companies Ranked by Revenue
3.3 Global HIV Associated Lipodystrophy Syndrome Treatment Revenue by Companies
3.4 Top 3 and Top 5 HIV Associated Lipodystrophy Syndrome Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies HIV Associated Lipodystrophy Syndrome Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 HIV Associated Lipodystrophy Syndrome Treatment Players in Global Market
  3.6.1 List of Global Tier 1 HIV Associated Lipodystrophy Syndrome Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 HIV Associated Lipodystrophy Syndrome Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Markets, 2021 & 2028
  4.1.2 Specific Drug Treatment
  4.1.3 Cosmetic Corrective Treatment
4.2 By Type - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue & Forecasts
  4.2.1 By Type - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2017-2022
  4.2.2 By Type - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2023-2028
  4.2.3 By Type - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Specialist Clinic
  5.1.4 Others
5.2 By Application - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue & Forecasts
  5.2.1 By Application - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2017-2022
  5.2.2 By Application - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2023-2028
  5.2.3 By Application - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2021 & 2028
6.2 By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue & Forecasts
  6.2.1 By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2017-2022
  6.2.2 By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2023-2028
  6.2.3 By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2017-2028
  6.3.2 US HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.3.3 Canada HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.3.4 Mexico HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2017-2028
  6.4.2 Germany HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.4.3 France HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.4.4 U.K. HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.4.5 Italy HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.4.6 Russia HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.4.8 Benelux HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2017-2028
  6.5.2 China HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.5.3 Japan HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.5.4 South Korea HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.5.6 India HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2017-2028
  6.6.2 Brazil HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.6.3 Argentina HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2017-2028
  6.7.2 Turkey HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.7.3 Israel HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028
  6.7.5 UAE HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Gilead Sciences
  7.1.1 Gilead Sciences Corporate Summary
  7.1.2 Gilead Sciences Business Overview
  7.1.3 Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
  7.1.4 Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2017-2022)
  7.1.5 Gilead Sciences Key News
7.2 Amgen
  7.2.1 Amgen Corporate Summary
  7.2.2 Amgen Business Overview
  7.2.3 Amgen HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
  7.2.4 Amgen HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2017-2022)
  7.2.5 Amgen Key News
7.3 Abbott
  7.3.1 Abbott Corporate Summary
  7.3.2 Abbott Business Overview
  7.3.3 Abbott HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
  7.3.4 Abbott HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2017-2022)
  7.3.5 Abbott Key News
7.4 AstraZeneca
  7.4.1 AstraZeneca Corporate Summary
  7.4.2 AstraZeneca Business Overview
  7.4.3 AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
  7.4.4 AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2017-2022)
  7.4.5 AstraZeneca Key News
7.5 AbbVie
  7.5.1 AbbVie Corporate Summary
  7.5.2 AbbVie Business Overview
  7.5.3 AbbVie HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
  7.5.4 AbbVie HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2017-2022)
  7.5.5 AbbVie Key News
7.6 GlaxoSmithKline
  7.6.1 GlaxoSmithKline Corporate Summary
  7.6.2 GlaxoSmithKline Business Overview
  7.6.3 GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
  7.6.4 GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2017-2022)
  7.6.5 GlaxoSmithKline Key News
7.7 Alfa Wassermann SPA
  7.7.1 Alfa Wassermann SPA Corporate Summary
  7.7.2 Alfa Wassermann SPA Business Overview
  7.7.3 Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
  7.7.4 Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2017-2022)
  7.7.5 Alfa Wassermann SPA Key News
7.8 Theratechnologies
  7.8.1 Theratechnologies Corporate Summary
  7.8.2 Theratechnologies Business Overview
  7.8.3 Theratechnologies HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
  7.8.4 Theratechnologies HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2017-2022)
  7.8.5 Theratechnologies Key News
7.9 Bristol-Myers Squibb
  7.9.1 Bristol-Myers Squibb Corporate Summary
  7.9.2 Bristol-Myers Squibb Business Overview
  7.9.3 Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
  7.9.4 Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2017-2022)
  7.9.5 Bristol-Myers Squibb Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. HIV Associated Lipodystrophy Syndrome Treatment Market Opportunities & Trends in Global Market
Table 2. HIV Associated Lipodystrophy Syndrome Treatment Market Drivers in Global Market
Table 3. HIV Associated Lipodystrophy Syndrome Treatment Market Restraints in Global Market
Table 4. Key Players of HIV Associated Lipodystrophy Syndrome Treatment in Global Market
Table 5. Top HIV Associated Lipodystrophy Syndrome Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies HIV Associated Lipodystrophy Syndrome Treatment Product Type
Table 9. List of Global Tier 1 HIV Associated Lipodystrophy Syndrome Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 HIV Associated Lipodystrophy Syndrome Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Gilead Sciences Corporate Summary
Table 31. Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 32. Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Amgen Corporate Summary
Table 34. Amgen HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 35. Amgen HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Abbott Corporate Summary
Table 37. Abbott HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 38. Abbott HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn), (2017-2022)
Table 39. AstraZeneca Corporate Summary
Table 40. AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 41. AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn), (2017-2022)
Table 42. AbbVie Corporate Summary
Table 43. AbbVie HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 44. AbbVie HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn), (2017-2022)
Table 45. GlaxoSmithKline Corporate Summary
Table 46. GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 47. GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Alfa Wassermann SPA Corporate Summary
Table 49. Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 50. Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Theratechnologies Corporate Summary
Table 52. Theratechnologies HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 53. Theratechnologies HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Bristol-Myers Squibb Corporate Summary
Table 55. Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 56. Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. HIV Associated Lipodystrophy Syndrome Treatment Segment by Type in 2021
Figure 2. HIV Associated Lipodystrophy Syndrome Treatment Segment by Application in 2021
Figure 3. Global HIV Associated Lipodystrophy Syndrome Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by HIV Associated Lipodystrophy Syndrome Treatment Revenue in 2021
Figure 8. By Type - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2017-2028
Figure 12. US HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2017-2028
Figure 16. Germany HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2017-2028
Figure 24. China HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Amgen HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Abbott HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. AbbVie HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Theratechnologies HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)